Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company targeting the pharmaceutical and domestic drug-manufacturing sector. The SPAC filed an amended registration statement on Form S-1/A with the SEC on September 16, 2025, indicating the vehicle was still in the registration process as of that date. The "II" designation signals that the sponsor team has previously brought a similar pharmaceutical-focused SPAC to market, making this a successor vehicle in the same thematic series. DMII is positioned to pursue a business combination within the healthcare and life-sciences supply-chain space, reflecting continued investor interest in domestic pharmaceutical production. Sign up at SpacDesk for full filing history, deal timelines, and real-time data on DMII and the broader SPAC market.